Related Experiment Video
Updated: Jun 23, 2026

Whole Blood Assay with Dual Co-Stimulation for Antigen-Specific Analysis of Host Immunity to Fungal and Viral Pathogens
Published on: September 20, 2024
The functioning antigens: beyond just as the immunological targets
Yoshihiko Hirohashi1, Toshihiko Torigoe, Satoko Inoda
1Department of Pathology, Sapporo Medical University School of Medicine, South-1 West 17, Chuo-ko, Sapporo, 060-8556 Japan.
Abstract:
Antigenic peptides derived from tumor-associated antigens (TAAs) facilitate peptide cancer vaccine therapies. With the recent progress in cancer immunity research, huge amounts of antigenic peptides have already been reported. Clinical trials using such peptides are underway now all over the world. Some reports have shown the efficacy of peptide vaccine therapies. However, others ended with unfavorable results, suggesting fundamental underlying problems. One major mechanism that negates the peptide vaccine therapy is tumor escape from immunological systems caused by loss of antigens. TAAs that are used in cancer vaccine therapies may be divided into two major groups: functioning antigens and nonfunctioning antigens. A 'functioning antigen' could be defined as a TAA that is essential for tumor growth, is expressed in several kinds of malignancies and shows homogenous expression in cancerous tissues. It is not difficult to imagine that antigen loss will occur easily with non-functioning antigens as a target of cancer vaccine therapy. Thus, it is essential to use functioning antigens for successful cancer vaccine therapy. In this review, we discuss the functioning antigens and their categorization in detail.
Insights
Targeting functioning tumor-associated antigens (TAAs) is crucial for effective peptide cancer vaccines. This review details functioning antigens to improve cancer immunotherapy outcomes and overcome tumor escape mechanisms.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- Peptide cancer vaccines utilize tumor-associated antigens (TAAs) to stimulate anti-tumor immunity.
- Despite progress, some peptide vaccine therapies face challenges due to tumor escape via antigen loss.
- TAAs are broadly categorized into functioning and non-functioning types, impacting vaccine efficacy.
Purpose of the Study:
- To review and categorize functioning tumor-associated antigens (TAAs) for improved cancer vaccine design.
- To highlight the importance of selecting appropriate TAAs to prevent tumor immune escape.
- To provide a framework for understanding TAAs in the context of successful cancer immunotherapy.
Main Methods:
- Literature review of existing research on tumor-associated antigens and cancer vaccine therapies.
- Analysis of TAA characteristics, focusing on criteria defining 'functioning antigens'.
- Categorization of TAAs based on their essentiality for tumor growth, expression patterns, and homogeneity.
Main Results:
- Functioning antigens are essential for tumor growth, broadly expressed across malignancies, and homogeneously present in cancerous tissues.
- Non-functioning antigens are more prone to antigen loss, leading to therapeutic failure.
- The selection of functioning TAAs is critical for overcoming tumor escape and enhancing peptide vaccine efficacy.
Conclusions:
- Utilizing functioning tumor-associated antigens is paramount for the success of peptide cancer vaccine therapies.
- Understanding TAA categorization aids in designing more robust and effective cancer immunotherapies.
- Further research into functioning antigens can optimize vaccine strategies and improve patient outcomes.
Related Concept Videos
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Special Features of Adaptive Immunity
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
Humoral Immune Responses
Diversity of Antigen Receptors
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
